INTRAVITREAL INJECTION OF BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION Results After 12 Months and Multiple Regression Analysis
INTRAVITREAL INJECTION OF BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION Results After 12 Months and Multiple Regression Analysis
复制标题
DOI：
10.1097/iae.0b013e3181aa8e20
复制
发表时间：
2009-10-01
影响因子：
3.3
通讯作者：
Terasaki, Hiroko
中科院分区：
文献类型：
--
作者：
Kondo, Mineo;Kondo, Nagako;Terasaki, Hiroko
目的：评价玻璃体内贝伐单抗治疗继发于视网膜分支静脉阻塞的黄斑水肿的12个月随访结果，并确定与最终视力outcome.Methods的改善相关的预处理因素：50例继发于视网膜分支静脉阻塞的黄斑水肿患者的50只眼接受了1.25 mg/0.05 mL贝伐单抗注射。当黄斑水肿复发或治疗无效时，进行额外的注射。测量最佳矫正视力和中心凹厚度。逐步多元回归分析也performed.Results：平均对数的最小分辨率的视力角从0.53到0.26显着改善，平均中心凹厚度显着下降，从523到305 μ m在12个月的随访期间。平均进样次数为2.0（范围：1-4）。逐步多元回归分析显示，年轻患者在12个月时视力更好，在12个月期间视力改善更大。此外，更好的治疗前视力与更好的视力在12个月，但改善较少的visualacuity.Conclusion：玻璃体内贝伐单抗治疗继发于视网膜分支静脉阻塞的黄斑水肿可以是一个长期有效的治疗。视网膜29：1242-1248，2009
Purpose: To evaluate the 12-month follow-up results of intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion and to identify the pretreatment factors that were associated with an improvement of the final visual outcome.Methods: Fifty eyes of 50 patients with macular edema secondary to branch retinal vein occlusion received an injection of 1.25 mg/0.05 mL bevacizumab. Additional injections were done when recurrence of macular edema occurred or the treatment was not effective. The best-corrected visual acuity and foveal thickness were measured. Stepwise multiple regression analyses were also performed.Results: The mean logarithm of the minimum angle of resolution visual acuity improved significantly from 0.53 to 0.26, and the mean foveal thickness decreased significantly from 523 to 305 mu m during the 12-month follow-up period. The mean number of injections was 2.0 (range, 1-4). Stepwise multiple regression analyses showed that younger patients had both better visual acuity at 12 months and greater improvement of visual acuity during 12 months. In addition, better pretreatment visual acuity was associated with better visual acuity at 12 months but with less improvement of the visual acuity.Conclusion: Intravitreal bevacizumab therapy can be a long-term effective treatment for macular edema secondary to branch retinal vein occlusion. RETINA 29:1242-1248, 2009